Nektar Therapeutics (NKTR)
- Previous Close
1.6700 - Open
1.7300 - Bid 1.5500 x 1200
- Ask 1.5800 x 1200
- Day's Range
1.5500 - 1.7400 - 52 Week Range
0.4100 - 1.7900 - Volume
1,139,593 - Avg. Volume
2,605,883 - Market Cap (intraday)
306.641M - Beta (5Y Monthly) 0.91
- PE Ratio (TTM)
-- - EPS (TTM)
-1.4500 - Earnings Date May 9, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
2.00
Nektar Therapeutics, a biopharmaceutical company, focuses on discovering and developing medicines in the field of immunotherapy in the United States and internationally. The company is developing rezpegaldesleukin, a cytokine Treg stimulant that is in phase 2 clinical trial for the treatment of systemic lupus erythematosus and ulcerative colitis, as well as phase 2b clinical trial to treat atopic dermatitis and psoriasis; and NKTR-255, an IL-15 receptor agonist, which is in phase 1 clinical trial to boost the immune system's natural ability to fight cancer. It has collaboration agreements with Takeda Pharmaceutical Company Ltd.; AstraZeneca AB; UCB Pharma S.A.; F. Hoffmann-La Roche Ltd; Bausch Health Companies Inc.; Pfizer Inc.; Amgen Inc.; UCB Pharma (Biogen); Bristol-Myers Squibb Company; Merck KGaA; and SFJ Pharmaceuticals, Inc. The company was incorporated in 1990 and is headquartered in San Francisco, California.
www.nektar.comRecent News: NKTR
Performance Overview: NKTR
Trailing total returns as of 5/3/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: NKTR
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: NKTR
Valuation Measures
Market Cap
306.64M
Enterprise Value
120.80M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
3.52
Price/Book (mrq)
2.34
Enterprise Value/Revenue
1.34
Enterprise Value/EBITDA
-0.50
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-15.25%
Return on Equity (ttm)
-110.95%
Revenue (ttm)
90.12M
Net Income Avi to Common (ttm)
-276.06M
Diluted EPS (ttm)
-1.4500
Balance Sheet and Cash Flow
Total Cash (mrq)
303.62M
Total Debt/Equity (mrq)
175.90%
Levered Free Cash Flow (ttm)
-63.63M
Research Analysis: NKTR
Company Insights: NKTR
Fair Value
Dividend Score
Hiring Score
Insider Sentiment Score
Research Reports: NKTR
NKTR: Lowering target price to $0.58
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.584000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Low; and a Value Subrating of Low.
RatingPrice TargetNKTR: Lowering target price to $0.63
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.632000; an Industry Subrating of Medium; a Management Subrating of Medium; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of High; and a Value Subrating of Low.
RatingPrice TargetNKTR: Lowering target price to $0.93
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $0.928000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice TargetNKTR: What does Argus have to say about NKTR?
NEKTAR THERAPEUTICS has an Investment Rating of SELL; a target price of $1.000000; an Industry Subrating of Medium; a Management Subrating of Low; a Safety Subrating of Low; a Financial Strength Subrating of Low; a Growth Subrating of Medium; and a Value Subrating of Low.
RatingPrice Target